- 4 -

SIDNEY et al.

Appl. No. *To be assigned* Docket No.: 2060.0330002/EKS/M-M

Amendments to the Claims

- (original) A composition comprising one or more peptides from any of Tables
 11-29.
- 2. (original) A composition comprising nucleic acids encoding one or more peptides from any of Tables 11-29.
- 3. (currently amended) The composition of claim 1[[or 2]], wherein at least one of the one or more peptides is an HTL epitope.
- 4. (currently amended) The composition of claim 1[[or 2]], wherein at least one of the one or more peptides is a CTL epitope.
- 5. (original) The composition of claim 4, further comprising an HTL epitope.
- 6. (currently amended) The composition of claim 1[[or 2]], further comprising a spacer molecule.
- 7. (currently amended) The composition of claim 1[[or 2]], further comprising a carrier.
- 8. (currently amended) The composition of claim 1[[or 2]], further comprising an MHC targeting sequence.
- (currently amended) The composition of claim 1[[or 2]], further comprising a lipid.
- 10. (currently amended) The composition of claim 1[[or 2]], wherein the one or more peptides are incorporated as part of a liposome.
- 11. (currently amended) The composition of claim 1[[or 2]], wherein at least one of the one or more peptides is a heteropolymer.

Docket No.: 2060.0330002/EKS/M-M

- 12. (currently amended) The composition of claim 1[[or 2]], wherein at least one of the one or more peptides is a homopolymer.
- one or more peptides is a peptide from an antigen selected from the group consisting of prostate specific antigen (PSA), prostate specific membrane antigen (PSM), hepatitis B virus (HBV) antigen, hepatitis C virus (HCV) antigen, malignant melanoma antigen (MAGE), Epstein Barr virus, human immunodeficiency type-1 (HIV-1), human immunodeficiency type-2 (HIV-2), papilloma virus, Lassa virus, mycobacterium tuberculosis (MT), p53, murine p53 (mp53), CEA, HER2/neu, and tyrosine kinase related protein (TKP).
- 14. (currently amended) A pharmaceutical composition comprising an active ingredient, wherein the active ingredient comprises the composition of claim 1[[or 2]].
- 15. (currently amended) A vaccine composition comprising an active ingredient, wherein the active ingredient comprises the composition of claim 1[[or 2]].
- 16. (currently amended) The use of the composition of claim 1 any of claims 1, 2, 14 or 15, wherein the composition is a prophylactic composition for the prevention of viral infection or cancer.
- 17. (currently amended) The use of the composition of <u>claim 1 any of claims 1, 2, 14 or</u>

 15, wherein the composition is a therapeutic composition for the treatment of viral infection or cancer.
- 18. (currently amended) A diagnostic reagent comprising the composition of claim 1[[or 2]].

SIDNEY et al.

Appl. No. To be assigned Docket No.: 2060.0330002/EKS/M-M

(original) The use according to claim 17, for the treatment of prostate cancer, 19. hepatitis B, hepatitis C, AIDS, renal carcinoma, cervical carcinoma, lymphoma, CMV or chondyloma acuminatum.